With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

Asiawu Imam says the therapy will make a huge difference A gene-editing ... not everyone with sickle cell will be eligible for the potentially life-changing benefits of Casgevy.

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

A gene-editing therapy for sickle cell disease, with a price tag of £ ... called it a "monumental step forward", and said the one-off treatment Casgevy, also known as Exa-cel, "holds a very ...